ArticleJACC. Asia2025
Impact of Nonadherence to Any Antiplatelet Therapy After PCI With Drug-Eluting Stents on Critical Outcomes.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- New-Onset Atrial Fibrillation and Accelerated Kidney Function Decline in Working-Age Adults.JAMA network open · 2026Article
- Patient Education Deficits and Medication Knowledge Gaps Among Post-Percutaneous Coronary Intervention Patients: A Cross-Sectional Study of Communication Quality and Adherence in Saudi Cardiac Care.Healthcare (Basel, Switzerland) · 2026Article
- Theory of Planned Behaviour Constructs as Predictors of Antiplatelet Medication Adherence Following Percutaneous Coronary Intervention: A Cross-Sectional Study in Saudi Arabia.Healthcare (Basel, Switzerland) · 2026Article
- Pathways of Care for Patients Who Undergo Primary Percutaneous Coronary Intervention for STEMI: A Review of "Reviews in cardiovascular medicine · 2026Review
- Healthcare Professionals' Perspectives on Barriers and Facilitators to Medication Adherence Post Myocardial Infarction: A Qualitative Study Using the Theoretical Domains Framework.Pharmacy (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLifelong antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is strongly recommended. However, the extent and temporal variation in the risk of nonadherence to this recommendation remain unclear.
objectivesThe aim of this study was to investigate how nonadherence to any antiplatelet therapy after PCI affects critical cardiac events and whether this effect varies over time.
methodsThis cohort study analyzed Japanese nationwide insurance claims and health checkup records of working-age patients who underwent PCI with DES between April 2016 and March 2022. Nonadherence was defined as prescription coverage of antiplatelet therapy <50% within preceding 90 days. Landmark-time survival analysis with propensity-score matching was conducted every 5 days from 90th to 1,095th days after PCI. The primary outcome was a composite of all-cause death, myocardial infarction, or cardiopulmonary arrest. Results were synthesized to assess temporal variation in the risk magnitude.
resultsAmong 40,902 patients (mean age, 58.3 ± 8.3 years; 5.5% women [2,240 of 40,902], median [IQR] follow-up: 653 days [Q1-Q3: 235-1,233 days]), nonadherence was observed in 1.18% (421 of 35,582) at 90 days and 4.70% (579 of 12,312) at 1,095 days after PCI. Critical cardiac events were more frequent in nonadherent patients (HR: 2.50 [95% CI: 1.92-3.26]; P < 0.001), with no significant temporal variation across landmark times.
conclusionsNonadherence to any antiplatelet therapy after PCI was associated with a more than 2-fold increase in critical cardiac events, irrespective of post-PCI timing throughout 3 years. These findings emphasize the need for sustained efforts by health care providers and patients to maintain drug adherence over a prolonged period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.